David M Asmuth

List of Publications by Year
in descending order

71 papers	3,249 citations	172457 29 h-index	149698 56 g-index
74 all docs	74 docs citations	74 times ranked	4991 citing authors

#	Article	IF	Citations
1	Potential use of <scp>serumâ€derived</scp> bovine immunoglobulin/protein isolate for the management of <scp>COVID</scp>â€19. Drug Development Research, 2021, 82, 873-879.	2.9	5
2	Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV,the, 2021, 8, e397-e407.	4.7	42
3	Women are from venus: implications for diversified sex-based preexposure prophylaxis approaches. Aids, 2021, 35, 1691-1693.	2.2	0
4	HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens. PLoS ONE, 2020, 15, e0224875.	2.5	3
5	Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial. Clinical Nutrition, 2019, 38, 1303-1309.	5.0	14
6	Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption. PLoS ONE, 2019, 14, e0210965.	2.5	8
7	Delayed gastrointestinal-associated lymphoid tissue reconstitution in duodenum compared with rectum in HIV-infected patients initiating antiretroviral therapy. Aids, 2019, 33, 2289-2298.	2.2	6
8	Serum Bovine Immunoglobulins Improve Inflammation and Gut Barrier Function in Persons with HIV and Enteropathy on Suppressive ART. Pathogens and Immunity, 2019, 4, 124.	3.1	10
9	Hepatic Safety of Maraviroc in Patients with HIV-1 and Hepatitis C and/or B Virus: 144-Week Results from a Randomized, Placebo-Controlled Trial. Antiviral Therapy, 2017, 22, 263-269.	1.0	6
10	Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 216, 813-818.	4.0	12
11	Evaluation of oral serum-derived bovine immunoglobulins in HIV-infected patients with chronic idiopathic diarrhea. HIV Clinical Trials, 2017, 18, 205-213.	2.0	2
12	Associations of Plasma Cytokine and Microbial Translocation Biomarkers With Immune Reconstitution Inflammatory Syndrome. Journal of Infectious Diseases, 2017, 216, 1159-1163.	4.0	12
13	Continued Elevation of Interleukin-18 and Interferon-Î³ After Initiation of Antiretroviral Therapy and Clinical Failure in a Diverse Multicountry Human Immunodeficiency Virus Cohort. Open Forum Infectious Diseases, 2016, 3, ofw118.	0.9	19
14	Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients NaÃ¯ve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathogens, 2016, 12, e1005381.	4.7	37
15	Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 31-38.	2.1	71
16	Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 123-129.	2.1	54
17	Peginterferon Î±-2a for the treatment of HIV infection. Expert Opinion on Investigational Drugs, 2016, 25, 249-257.	4.1	7
18	Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults. Journal of Infectious Diseases, 2016, 214, 65-72.	4.0	55

#	Article	IF	Citations
19	Role of intestinal myofibroblasts in HIV-associated intestinal collagen deposition and immune reconstitution following combination antiretroviral therapy. Aids, 2015, 29, 877-888.	2.2	18
20	Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Caseâ€“Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 163-171.	2.1	21
21	Differential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivo. Journal of AIDS & Clinical Research, 2015, 06, .	0.5	7
22	C-Reactive Protein (CRP), Interferon Gamma-Inducible Protein 10 (IP-10), and Lipopolysaccharide (LPS) Are Associated with Risk of Tuberculosis after Initiation of Antiretroviral Therapy in Resource-Limited Settings. PLoS ONE, 2015, 10, e0117424.	2.5	23
23	Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. HIV Clinical Trials, 2015, 16, 72-80.	2.0	8
24	Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection. JAMA - Journal of the American Medical Association, 2014, 312, 353.	7.4	236
25	Mucosal immunity in HIV infection. Current Opinion in Infectious Diseases, 2014, 27, 275-281.	3.1	12
26	Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4Ã—: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2014, 14, 291-300.	9.1	100
27	Clinical and Immunologic Predictors of Death After an Acute Opportunistic Infection: Results from ACTG A5164. HIV Clinical Trials, 2014, 15, 133-139.	2.0	9
28	HIV infection and atherosclerosis: evaluating the drivers of inflammation. European Journal of Preventive Cardiology, 2013, 20, 720-728.	1.8	36
29	HIV Disease Activity as a Modulator of Lipoprotein(a) and Allele-Specific Apolipoprotein(a) Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 387-392.	2.4	25
30	Impact of highly active antiretroviral therapy initiation on CD4+ T-cell repopulation in duodenal and rectal mucosa. Aids, 2013, 27, 867-877.	2.2	29
31	Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy. Aids, 2013, 27, 2207-2217.	2.2	63
32	Host Gene Expression Changes Correlating With Antiâ€“HIV-1 Effects in Human Subjects After Treatment With Peginterferon Alfa-2a. Journal of Infectious Diseases, 2012, 205, 1443-1447.	4.0	22
33	Elevated Interleukin 8 and T-Helper 1 and T-Helper 17 Cytokine Levels Prior to Antiretroviral Therapy in Participants Who Developed Immune Reconstitution Inflammatory Syndrome During ACTG A5164. Journal of Infectious Diseases, 2012, 206, 1715-1723.	4.0	50
34	Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection. Antimicrobial Agents and Chemotherapy, 2012, 56, 6372-6378.	3.2	15
35	Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens. Aids, 2012, 26, 1625-1634.	2.2	23
36	Randomized pilot trial of a synbiotic dietary supplement in chronic HIV-1 infection. BMC Complementary and Alternative Medicine, 2012, 12, 84.	3.7	63

#	Article	IF	Citations
37	Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCVâ€monoinfection and HIV/HCVâ€coinfection. Journal of Medical Virology, 2012, 84, 431-437.	5.0	13
38	Interferon-Alpha Administration Enhances CD8+ T Cell Activation in HIV Infection. PLoS ONE, 2012, 7, e30306.	2.5	42
39	Molecular Characterization of Stool Microbiota in HIV-Infected Subjects by Panbacterial and Order-Level 16S Ribosomal DNA (rDNA) Quantification and Correlations With Immune Activation. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 363-370.	2.1	108
40	HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. Aids, 2011, 25, 159-164.	2.2	32
41	Lessons from maraviroc clinical trials. Expert Review of Anti-Infective Therapy, 2011, 9, 649-651.	4.4	8
42	Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV coâ€infected patients. Journal of Medical Virology, 2010, 82, 791-798.	5.0	12
43	Comparative Cellâ€Mediated Immunogenicity of DNA/DNA, DNA/Adenovirus Type 5 (Ad5), or Ad5/Ad5 HIVâ€1 Clade BgagVaccine Primeâ€Boost Regimens. Journal of Infectious Diseases, 2010, 201, 132-141.	4.0	47
44	Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfaâ€2a in HIVâ€1â€“Monoinfected Participants: A Phase II Clinical Trial. Journal of Infectious Diseases, 2010, 201, 1686-1696.	4.0	118
45	CD4+ T-Cell Restoration After 48 Weeks in the Maraviroc Treatment-Experienced Trials MOTIVATE 1 and 2. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 394-397.	2.1	37
46	Quantitative 3D Video Microscopy of HIV Transfer Across T Cell Virological Synapses. Science, 2009, 323, 1743-1747.	12.6	437
47	Incomplete Reconstitution of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384. Clinical Infectious Diseases, 2009, 48, 350-361.	5.8	202
48	UC Davis CTSA: Coming of Age. Clinical and Translational Science, 2009, 2, 98-101.	3.1	3
49	Replication Capacity in Relation to Immunologic and Virologic Outcomes in HIV-1-Infected Treatment-Naive Subjects. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 250-258.	2.1	12
50	IL-7 administration drives T cellâ€“cycle entry and expansion in HIV-1 infection. Blood, 2009, 113, 6304-6314.	1.4	291
51	Nineâ€color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part I: Panel design by an empiric approach. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 400-410.	1.5	65
52	Nineâ€color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part II: Panel performance across different instrument platforms. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 411-420.	1.5	25
53	Multifunctional Human Immunodeficiency Virus (HIV) Gag-Specific CD8 + T-Cell Responses in Rectal Mucosa and Peripheral Blood Mononuclear Cells during Chronic HIV Type 1 Infection. Journal of Virology, 2007, 81, 5460-5471.	3.4	83
54	Evidence for Calpain-Mediated Androgen Receptor Cleavage as a Mechanism for Androgen Independence. Cancer Research, 2007, 67, 9001-9005.	0.9	120

#	Article	IF	Citations
55	E2F1 expression in LNCaP prostate cancer cells deregulates androgen dependent growth, suppresses differentiation, and enhances apoptosis. Prostate, 2006, 66, 70-81.	2.3	33
56	Effect of Baseline- and Treatment-Related Factors on Immunologic Recovery After Initiation of Antiretroviral Therapy in HIV-1-Positive Subjects. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 426-434.	2.1	148
57	Estimating cell death in G2M using bivariate BrdUrd/DNA flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2005, 66A, 32-40.	1.5	3
58	Cell cycle kinetic dysregulation in HIV-infected normal lymphocytes. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2005, 66A, 41-51.	1.5	4
59	Treatments for Hepatitis B. Clinical Infectious Diseases, 2004, 39, 1353-1362.	5.8	12
60	Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection. Antiviral Research, 2004, 63, 123-131.	4.1	10
61	A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Research, 2004, 64, 103-111.	4.1	30
62	Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection. Transfusion, 2003, 43, 451-458.	1.6	11
63	Cytomegalovirus Glycoprotein B Groups in Human Immunodeficiency Virusâ€"Infected Patients with Incident Retinitis. Journal of Infectious Diseases, 2002, 186, 114-117.	4.0	24
64	Entrapment of recent thymic emigrants in lymphoid tissues from HIV-infected patients. Aids, 2002, 16, 2119-2127.	2.2	18
65	<title>Importance of high-throughput cell separation technologies for genomics/proteomics-based clinical diagnostics</title>. , 2002, , .		1
66	Chemokine/CD4 receptor density ratios correlate with HIV replication in lymph node and peripheral blood of HIV-infected individuals. Aids, 2001, 15, 161-169.	2.2	30
67	Homeostasis of Naive and Memory T Cell Subpopulations in Peripheral Blood and Lymphoid Tissues in the Context of Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2001, 183, 1336-1342.	4.0	9
68	`Modeling' relationships among HIV-1 replication, immune activation and CD4+ T-cell losses using adjusted correlative analyses. Aids, 2000, 14, 951-958.	2.2	60
69	Changing Patterns of Infections in Patients with AIDS: A Study of 279 Autopsies of Prison Inmates and Nonincarcerated Patients at a University Hospital in Eastern Texas, 1984-1993. Clinical Infectious Diseases, 1996, 23, 241-247.	5.8	28
70	Physiological effects of HIV infection on human intestinal epithelial cells. Aids, 1994, 8, 205.	2.2	35
71	Microsporidia and diarrhea in AIDS patients. Clinical Microbiology Newsletter, 1994, 16, 179-183.	0.7	2